We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Congress Says Biogen Used FDA Relationships to Launch Unproven Alzheimer’s Drug
Congress Says Biogen Used FDA Relationships to Launch Unproven Alzheimer’s Drug
Trading on an inside-track relationship with FDA regulators, Biogen leveraged the Accelerated Approval pathway to bring to market its controversial antiamyloid antibody, Aduhelm (aducanumab), an 18-month Congressional investigation has found.